# EDGAR Filing Document

**Accession Number:** 0001801198
**File Stem:** 0001171843-25-003860
**Filing Date:** 2025-6
**Character Count:** 4953
**Document Hash:** 0c2bece5bd61e53e86a311cd0604535c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-25-003860.hdr.sgml**: 20250612

**ACCESSION NUMBER**: 0001171843-25-003860

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250612

**FILED AS OF DATE**: 20250612

**DATE AS OF CHANGE**: 20250612

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Legend Biotech Corp
- **CENTRAL INDEX KEY:** 0001801198
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39307
- **FILM NUMBER:** 251042605

**BUSINESS ADDRESS:**
- **STREET 1:** 2101 COTTONTAIL LANE
- **CITY:** SOMERSET
- **STATE:** NJ
- **ZIP:** 08873
- **BUSINESS PHONE:** 732-850-5598

**MAIL ADDRESS:**
- **STREET 1:** 2101 COTTONTAIL LANE
- **CITY:** SOMERSET
- **STATE:** NJ
- **ZIP:** 08873

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549** 

**FORM 6-K**

**Report of Foreign Private Issuer** 

**Pursuant to Rule 13a-16 or 15d-16** 

**of the Securities Exchange Act of 1934**

**Date of Report: June 12, 2025**

**Commission File Number: 001-39307** 

**Legend Biotech Corporation**

**(Exact Name of Registrant as Specified in its Charter)**

**2101 Cottontail Lane** 

**Somerset, New Jersey 08873** 

**(Address of principal executive office)** 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

On June 12, 2025, Legend Biotech Corporation (the "Company") held its 2025 Annual General Meeting of Shareholders. The voting results are attached hereto as Exhibit 99.1.

This report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference in the registration statements of the Company on Form F-3 (Nos. 333-257625, 333-272222 and 333-278050) and Form S-8 (No. 333-239478 and 333-283217), to the extent not superseded by documents or reports subsequently filed.

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit** | **Title** |
| [99.1](exh_991.htm) | [Voting Results of Annual General Meeting](exh_991.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **LEGEND BIOTECH CORPORATION** | **LEGEND BIOTECH CORPORATION** |
| Date: June 12, 2025 | By: | /s/ Ying Huang |
|  | Name: | Ying Huang, Ph.D. |
|  | Title: | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Voting Results of 2025 Annual General Meeting**

At Legend Biotech Corporation's (the "Company") annual general meeting of shareholders held on June 12, 2025 (the "AGM"), the Company's shareholders:

&nbsp;&nbsp;&nbsp;&nbsp;· received the audited consolidated financial statements of the Company for the fiscal year ended December
31, 2024;

&nbsp;&nbsp;&nbsp;&nbsp;· ratified the appointment of Ernst & Young LLP as the Company's independent auditor for the
fiscal year ending December 31, 2025;

&nbsp;&nbsp;&nbsp;&nbsp;· re-elected each of Dr. Patrick Casey, Mr. Yau Wai Man Philip and Dr. Fangliang Zhang to serve as a Class
II director for a three-year term; and

&nbsp;&nbsp;&nbsp;&nbsp;· authorized each of the directors and officers of the Company to take any and every action that might
be necessary to effect the forgoing resolutions as such director or officer, in his or her absolute discretion, thinks fit.

A total of approximately 341,943,628 ordinary shares, including those underlying ADSs, representing approximately 92.8% of the ordinary shares issued and outstanding as of May 7, 2025, the record date, were present in person or by proxy at the AGM. The results of the votes are as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **For** | **For** | **Against** | **Against** | **Abstain** | **Abstain** |
| <br>**Resolutions** | **Votes** | **%** | **Votes** | **%** | **Votes** | **%** |
| **Reception of Audited Financial Statements** | 341805292 | 92.737 *%* | 6184 | 0.002 *%* | 132152 | 0.036 *%* |
| **Ratification of appointment of Ernst & Young LLP as Independent Auditor for Fiscal Year 2025** | 341855596 | 92.750 *%* | 7490 | 0.002 *%* | 80542 | 0.022 *%* |
| **Election of Directors** |  |  |  |  |  |  |
| Dr. Patrick Casey (Class II) | 336842366 | 91.390 *%* | 4990816 | 1.354 *%* | 110446 | 0.030 *%* |
| Mr. Yau Wai Man Philip (Class II) | 318544258 | 86.425 *%* | 23313264 | 6.325 *%* | 86106 | 0.023 *%* |
| Dr. Fangliang Zhang<br> (Class II) | 327927312 | 88.971 *%* | 13929848 | 3.779 *%* | 86468 | 0.023 *%* |
| **Authorization of Directors and Officers** | 341728190 | 92.716 *%* | 126066 | 0.034 *%* | 89372 | 0.024 *%* |

---